|Security||TGXSF / Tigenix Sa (88675R109)|
Short Interest, Volume, and Squeeze
TGXSF / Tigenix Sa short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.
- Short Volume
- Total number of short shares traded on the major US markets each day
- Short Percent
- Total number of short shares traded divided by the total shares traded each day
- Short Interest
- Total number of open short positions of a security, divided by the total float (not shown)
- Short Squeeze
- When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.
Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.
|Market Date||Total Volume||Short Volume||Short Percent|
Related News Stories
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.
Today we will focus on Aclaris Therapeutics (ACRS). As we had expected, the FDA has approved its ESKATA topical solution, 40% for the treatment of raised seborrheic keratosis (non-cancerous skin growth). We had noted in our recent article that based on the data, an approval was likely. And as we expected, the stock has seen a pullback post approval. (142-3)
Even with an FDA approval, I have doubts about its sales, due to two existing approved drugs. (42-3)